The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide

Kim, Hong; Seo, Eun‐Hye; Lee, Seung–Hyun; Kim, Bumjoon J.

doi:10.20944/preprints201611.0060.v1

Cited by 17 publications

(2 citation statements)

References 23 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term therapy with this combination was very well tolerated and produced the highest anti-Aβ IgG titers compared with other regimens. 61 UB-311, a synthetic peptide used as Aβ vaccine, has been advanced into an ongoing phase 2 study in patients with mild 7 and moderate AD. In phase 1, it induced a 100% responder rate in patients with AD.…”

Section: Reduction Of Aβ-plaque Burden Via Drugs Interfering With Metmentioning

confidence: 99%

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou

Papageorgiou

2020

J Cent Nerv Syst Dis

544

378

View full text Add to dashboard Cite

Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine. To block the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation. Other underlying mechanisms are targeted by neuroprotective, anti-inflammatory, growth factor promotive, metabolic efficacious agents and stem cell therapies. Recent therapies have integrated multiple new features such as novel biomarkers, new neuropsychological outcomes, enrollment of earlier populations in the course of the disease, and innovative trial designs. In the near future different specific agents for every patient might be used in a “precision medicine” context, where aberrant biomarkers accompanied with a particular pattern of neuropsychological and neuroimaging findings could determine a specific treatment regimen within a customized therapeutic framework. In this review, we discuss potential disease-modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD.

show abstract

Section: Reduction Of Aβ-plaque Burden Via Drugs Interfering With Metmentioning

confidence: 99%

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou

Papageorgiou

2020

J Cent Nerv Syst Dis

544

378

View full text Add to dashboard Cite

show abstract

“…A special CPP, GV1001, a 16‐amino acid peptidase derived from human telomerase reverse transcriptase (hTERT), was reported in 2013 131 . Compared to other CPPs that pierce cell membranes by electrostatic interaction with proteoglycan, GV1001 can deliver macromolecules into the cell by forming complexes with extracellular heat shock proteins 90 and 70 131,132 . Its role as an anti‐cancer vaccine peptide has been reported in treating advanced pancreatic cancer, 133,134 non‐small cell lung cancer, 135 melanoma 136 and prostate cancer 137 .…”

Section: Cpps and Anti‐cancer Cargoes Deliverymentioning

confidence: 99%

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Zhou

Zou

Cheng

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

Due to the complex physiological structure, microenvironment and multiple physiological barriers, traditional anti‐cancer drugs are severely restricted from reaching the tumour site. Cell‐penetrating peptides (CPPs) are typically made up of 5–30 amino acids, and can be utilised as molecular transporters to facilitate the passage of therapeutic drugs across physiological barriers. Up to now, CPPs have widely been used in many anti‐cancer treatment strategies, serving as an excellent potential choice for oncology treatment. However, their drawbacks, such as the lack of cell specificity, short duration of action, poor stability in vivo, compatibility problems (i.e. immunogenicity), poor therapeutic efficacy and formation of unwanted metabolites, have limited their further application in cancer treatment. The cellular uptake mechanisms of CPPs involve mainly endocytosis and direct penetration, but still remain highly controversial in academia. The CPPs‐based drug delivery strategy could be improved by clever design or chemical modifications to develop the next‐generation CPPs with enhanced cell penetration capability, stability and selectivity. In addition, some recent advances in targeted cell penetration that involve CPPs provide some new ideas to optimise CPPs.

show abstract

Introduction

Langel

2023

CPP, Cell-Penetrating Peptides

View full text Add to dashboard Cite

The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide

Cited by 17 publications

References 23 publications

Current and Future Treatments in Alzheimer Disease: An Update

Current and Future Treatments in Alzheimer Disease: An Update

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Introduction

Contact Info

Product

Resources

About